Overview

Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The program will provide early access to the investigational drug gilotrif in patients with advanced non-small cell lung cancer who have failed at least 6 months on erlotinib or gefitinib. The Compassionate Use Programme will also provide additional safety information on gilotrif use.
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Afatinib
Erlotinib Hydrochloride
Gefitinib